Best AI News today

Tempus AI — AI News Today

United States flagUnited States

Tempus AI — a US precision-medicine company applying AI to clinical and molecular data for oncology and diagnostics. Acquired Personalis for $1.5B in 2026.

www.tempus.com

139 stories mentioning Tempus AI

20 from search

About Tempus AI

Tempus AI is an AI company. Tempus AI — a US precision-medicine company applying AI to clinical and molecular data for oncology and diagnostics. Acquired Personalis for $1.5B in 2026. This page tracks 139 recent news stories about Tempus AI, curated from 30+ sources and updated every 15 minutes.

139 stories
2 of 5 Top Stories
Breaking
Tempus AI to Acquire Personalis in $1.5 Billion Deal, Deepening Its Foothold in Cancer Monitoring
BreakingMedia

Tempus AI to Acquire Personalis in $1.5 Billion Deal, Deepening Its Foothold in Cancer Monitoring

Tempus AI, the Chicago startup that has become a lightning rod for hype around artificial intelligence in medicine, is making its boldest move yet by acquiring Personalis for $1.5 billion, a deal that would give the company direct control over the genetic sequencing technology used to monitor cancer patients. The acquisition signals that Tempus believes the real money in AI-driven oncology lies not just in analyzing medical data, but in owning the pipeline that generates it in the first place. For patients, the question is whether consolidating these tools will accelerate lifesaving innovations or simply give one company more control over a critical gateway to personalized cancer treatment.

Oncodaily faviconOncodaily·
RelatedAI & MoneyAI & Medicine

16 sources

Built In Chicago faviconBuilt In ChicagoBarron's faviconBarron'sBusiness Wire faviconBusiness Wire
Dimensional Fund Advisors LP Has $1.85 Million Stock Holdings in Tempus AI, Inc. $TEM
Media

Dimensional Fund Advisors LP Has $1.85 Million Stock Holdings in Tempus AI, Inc. $TEM

marketbeat.com faviconmarketbeat.com·
Media

Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead

TradingView faviconTradingView·
Media

3 Stocks That May Be Trading Below Intrinsic Value Estimates By Up To 48.5%

simplywall.st faviconsimplywall.st·
Media

Tempus AI CEO, data Ryan Fukushima sells $1,000,800 in shares

Investing.com faviconInvesting.com·

6 sources

Investing.com faviconInvesting.comMarketBeat faviconMarketBeat
Media

Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside

Yahoo Finance faviconYahoo Finance·
Media

Tempus AI (NASDAQ:TEM) Trading 7.5% Higher - Still a Buy?

marketbeat.com faviconmarketbeat.com·
Media

Leading AI Medtech Firm Achieves First Profit | Full Financial Report Reveals Non-AI Core Business Drives Revenue Growth

36Kr favicon36Kr·
Media

FDA Approves Tempus’ Tumor Only xT CDx

Medical Product Outsourcing faviconMedical Product Outsourcing·
Media

Tempus AI Expands Cancer Platform With Launch of ArteraAI Prostate Test For Metastatic Patients

Stocktwits faviconStocktwits·
Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $1,000,800.00 in Stock
Media

Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $1,000,800.00 in Stock

MarketBeat faviconMarketBeat·

9 sources

MarketBeat faviconMarketBeatInvesting.com faviconInvesting.com
BioNTech alumni launch AI cancer surveillance for 40M: No clinical proof yet
Media

BioNTech alumni launch AI cancer surveillance for 40M: No clinical proof yet

AI cancer surveillance startup Bios Life launches with $25M and a Tempus data alliance, deploying the Nucleotide Transformer genomics model to build continuously updated cancer risk profiles for 40...

Tech Times on MSN faviconTech Times on MSN·
Media

U.S. stocks move: AI application software stocks rise, Tempus AI (TEM.US) up over 6.6%

Bitget faviconBitget·
Media

Tempus AI, Inc. • Robinhood Token (TEM) Price, MarketCap, Charts and Fundamentals Info

BeInCrypto faviconBeInCrypto·
RelatedRobinhood
Media

Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

Yahoo Finance faviconYahoo Finance·
Media

Bios Life Emerges from Stealth with $25M and Partners with Tempus to Personalize Cancer Screening and Surveillance

synbiobeta.com faviconsynbiobeta.com·
Media

The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It's Not Tech)

24/7 Wall St. favicon24/7 Wall St.·
Media

Bios Life leaves stealth with $25M and a Tempus alliance for cancer surveillance

The Next Web faviconThe Next Web·
Media

Top Artificial Intelligence Stocks To Add to Your Watchlist - August 10th

MarketBeat faviconMarketBeat·

Frequently Asked Questions

What is Tempus AI?

Tempus AI is Tempus AI — a US precision-medicine company applying AI to clinical and molecular data for oncology and diagnostics. Acquired Personalis for $1.5B in 2026.

What is Tempus AI's official website?

Tempus AI's official website is https://www.tempus.com.

What is the latest news about Tempus AI?

As of today, there are 139 recent stories about Tempus AI. Recent headlines include: Dimensional Fund Advisors LP Has $1.85 Million Stock Holdings in Tempus AI, Inc. $TEM; Leading AI Medtech Firm Achieves First Profit | Full Financial Report Reveals Non-AI Core Business Drives Revenue Growth; Tempus AI, Inc. • Robinhood Token (TEM) Price, MarketCap, Charts and Fundamentals Info. Updated every 15 minutes.